Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: A clinical biomarker study

Pharmacogenetics and Genomics

Volumn 18, Issue 7, 2008, Pages 611-620

  Patrignani, Paola ^a   Di Febbo, Concetta ^a   Tacconelli, Stefania ^a   Douville, Karen ^b   Guglielmi, Maria D ^a   Horvath, Ryan J ^b   Ding, Min ^b   Sierra, Kent ^b   Stitham, Jeremiah ^b   Gleim, Scott ^b   Baccante, Giovanna ^a   Moretta, Valeria ^a   Di Francesco, Luigia ^a   Capone, Marta L ^a   Porreca, Ettore ^a   Hwa, John ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Deep vein thrombosis; Platelet activation; Polymorphisms; Prostacyclin; Prostacyclin receptor

Indexed keywords

11 OXOTHROMBOXANE B2; BIOLOGICAL MARKER; PADGEM PROTEIN; PROSTACYCLIN RECEPTOR; VON WILLEBRAND FACTOR; 11 DEHYDRO THROMBOXANE B2; 11-DEHYDRO-THROMBOXANE B2; DRUG DERIVATIVE; THROMBOXANE B2;

ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CLINICAL ARTICLE; COHORT ANALYSIS; COMMON CAROTID ARTERY; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION SYSTEM; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; MALE; MUTANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; URINALYSIS; AGED; BLOOD; GENETIC LINKAGE; GENETIC SCREENING; GENETICS; HYPERPLASIA; INTIMA; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; URINE; VEIN THROMBOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; GENETIC SCREENING; HUMANS; HYPERPLASIA; LINKAGE (GENETICS); MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, EPOPROSTENOL; THROMBOXANE B2; TUNICA INTIMA; VENOUS THROMBOSIS;

EID: 53049083243     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328301a774     Document Type: Article

References (42)

1. Heit JA. The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest 2003; 124:40S-48S.
2. Sobieszczyk P, Fishbein MC, Goldhaber SZ. Acute pulmonary embolism: don't ignore the platelet. Circulation 2002; 106:1748-1749.
3. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116:4-15.
4. Stitham J, Arehart EJ, Gleim SR, Douville KL, Hwa J. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat 2007; 82:95-108.
5. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79:1193-1226.
6. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-665.
7. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circulation Res 2005; 96:e1-e6.
8. 2. Science 2002; 296:539-541.
9. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 6:1954-1957.
10. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114:784-794.
11. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388:678-682.
12. Stitham J, Arehart EJ, Gleim SR, Douville KL, Hwa J. Arginine (CGC) codon targeting in the human prostacyclin receptor gene (PTGIR) and G-protein coupled receptors (GPCR). Gene 2007; 396:180-187.
13. Stitham J, Stojanovic A, Hwa J. Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 2002; 277:15439-15444.
14. Blann D, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77:1077-1780.
15. Fijnheer R, Frijns CJM, Korteweg J, Rommes H, Peters JH, Sixma JJ, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 7:1081-1085.
16. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67:1174-1177.
17. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004; 109:IV22-IV30.
18. 2 and prostacyclin in cigarette smokers. Circulation 2005; 112:1024-1029.
19. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992:66-70.
20. 2 metabolites in humans. Thromb Res 1987; 47:647-656.
21. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-1372.
22. 2 production in healthy subjects. Thromb Res 1980; 17:317-327.
23. Stitham J, Stojanovic A, Merenick BL, O'Hara KA, Hwa J. The unique ligandbinding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J Biol Chem 2003; 278:4250-4257.
24. Stitham J, Gleim SR, Douville K, Arehart E, Hwa J. Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function. J Biol Chem 2006; 281:37227-37236.
25. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
26. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous thromboembolism. Thromb Haemost 2001; 86:809-816.
27. Subramaniam M, Koedam JA, Wagner DD. Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol Biol Cell 1993; 4:791-801.
28. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol 2005; 45: 1467-1471.
29. Parmley JL, Hurst LD. How do synonymous mutations affect fitness? Bioessays 2007; 29:515-519.
30. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23:2131-217.
31. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Bloodborne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96:2311-2315.
32. 4 cooperative synthesis. Thromb Haemost 1994; 72:450-456.
33. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102:2720-2725.
34. Kanayama T, Kimura Y, Mizogami S. A new prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart. J Pharmacol Exp Ther 1993; 266:344-349.
35. Grandone E, Martinelli I, Margaglione M, Dragani A, Daví G. Platelet activation in subjects carrying factor V Leiden or factor II A20210 mutations. J Thromb Haemost 2006; 4:2496-2468.
36. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007; 82:85-94.
37. Quinton TM, Murugappan S, Kim S, Jin J, Kunapuli SP. Different G proteincoupled signaling pathways are involved in a granule release from human platelets. J Thromb Haemost 2004; 2:978-984.
38. Wilson SJ, Dowling JK, Zhao L, Carnish E, Smyth EM. Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization. Arterioscler Thromb Vasc Biol 2007; 27:290-296.
39. Migliacci R, Becattini C, Pesavento R, Davi G, Vedovati MC, Guglielmini G, et al. Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 2007; 92:812-818.
40. Young L, Ockelford P, Milne D, Rolfe-Vyson V, Mckelvie S, Harper P. Posttreatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4:1919-1924.
41. Zhang L, Bastepe M, Juppner H, Ruan KH. Characterization of the molecular mechanisms of the coupling between intracellular loops of prostacyclin receptor with the C-terminal domain of the Gα protein in human coronary artery smooth muscle cells. Arch Biochem Biophys 2006; 454:80-88.
42. Arehart E, Stitham J, Asselbergs FW, Douville K, MacKenzie T, Fetalvero KM, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition. Circ Res 2008 [Epub ahead of print].